Articles

New oncology reimbursements in Belgium

BJMO - volume 16, issue 3, may 2022

T. Feys MSc, MBA

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS

(BELG J MED ONCOL 2022;16(3):154–7)

Read more

New oncology reimbursements in Belgium

BJMO - volume 16, issue 2, march 2022

T. Feys MSc, MBA

OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2022;16(2):97)

Read more

Congress highlights 2022

BJMO - 2022, issue Special, may 2022

A. Enguita PhD, T. Feys MSc, MBA

In line with the tradition, the BMUC scientific committee asked a urologist, a radiation oncologist, and a medical oncologist to summarise the top stories presented during the large urology and oncology meetings of the past year.

Read more

Renal cell carcinoma

BJMO - 2022, issue Special, may 2022

T. Feys MSc, MBA

The second day of the 2022 annual BMUC meeting kicked off with a session addressing three hot topics in the field of kidney cancer. In a first lecture, Prof. Dr. Toni Choueiri (Dana Farber Cancer Institute, Boston, MA, USA) discussed the management of patients with non-clear cell renal cell carcinoma (RCC). Subsequently, Dr. Marco Gizzi (GHdC, Charleroi) turned the attention to the adjuvant treatment of patients with RCC after which he gave an overview of new molecules for patients with metastatic RCC. Dr. Stephanie Kroeze (Universitätsspital Zürich, Zürich, Switzerland) closed the RCC session with a presentation on how to combine radiotherapy with systemic therapy in this setting.

Read more

What is the role of the patient in the management of prostate cancer?

BJMO - 2022, issue Special, may 2022

A. Dekker MD, T. Feys MSc, MBA

What is the role of the patient in the management of prostate cancer? During BMUC 2022, André Deschamps, prostate cancer (PCa) patient and Chairman of Europa UOMO aimed to answer this question. In his lecture, he discussed the effect of PCa and its treatment on the daily life of patients and addressed some of the barriers and gaps that hamper a closer involvement of patients in the treatment decision process. 1

Read more

High-risk prostate carcinoma

BJMO - 2022, issue Special, may 2022

A. Dekker MD, T. Feys MSc, MBA

About 15% of patients with localised prostate cancer (PCa) are identified as having a high risk for disease recurrence and these patients account for the vast majority of PCa deaths. To date, however, the optimal treatment for patients with high-risk, localized PCa remains controversial. While it is important to offer these patients an effective treatment, this treatment should not come with excessive side effects or impact the patient’s quality of life (QoL).1 During a session at the 2022 BMUC meeting, the different treatment options for these patients were discussed from the perspective of the surgeon, the medical oncologist and the radiation oncologist.

Read more

How to stage primary prostate cancer in 2022

BJMO - 2022, issue Special, may 2022

J. Blokken PhD, PharmD, T. Feys MSc, MBA

Over the past years, next-generation imaging such as multiparametric whole body MRI and PSMA-PET/CT scans have been gaining momentum. Nonetheless, Prof. Padhani argues not to throw bone scintigraphy and CT scans (BS/ CT scans) out just yet. On the contrary, he puts BS/CT scans at the centre of patient care in men with locally advanced prostate cancer (LAPC). However, BS/ CT also comes with important limitations for which next-generation imaging (NGI) can serve as a problem solver after BS/CT scan assessments. During his talk at the BMUC 2022 meeting, Prof. Padhani emphasized the proven prognostic role of BS/CT scans, their predictive role in directing pelvic radiotherapy and for oncologic drug development. Finally, he argued that higher-quality evidence on the management and/or outcomes is needed before BS/CT scans can be substituted by NGI.1

Read more
X